Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

Vascular Health and Risk Management, 05/21/2012

This review aims to define where in community practice the use of vildagliptin as monotherapy is most desirable, focusing on segments of the population with type 2 diabetes mellitus that might receive the greatest benefit from vildagliptin in the management of their disease.

  • The efficacy and safety of the dipeptidyl peptidase–4 inhibitor, vildagliptin, as monotherapy have been widely confirmed in a large body of clinical studies of up to 2 years’ duration in various populations with type 2 diabetes mellitus.
  • This paper reviews the data supporting the use of vildagliptin in monotherapy.
  • Consideration based on baseline glycated hemoglobin levels and age is given to patient segments where metformin is not appropriate.
  • In addition, although prediabetes is not an indication, this manuscript briefly reviews some of the existing data showing that the mechanisms at work in diabetic populations are active in patients currently classified as prediabetic, with impaired glucose tolerance or impaired fasting glucose.
  • Finally, the rationale for vildagliptin dosing frequency in monotherapy is discussed.

Print Article Summary Cat 2 CME Report